Radical Abortion Activists Want Abortion Pills Over the Counter to Kill More Babies

Using suspect insider studies to push the myth of abortion pill safety, advocates have continued to push for relaxed distribution standards for mifepristone even as evidence of the pill’s dangers mounted. Now, while the Food and Drug Administration (FDA) is in the midst of a critical safety review of the drug in light of alarming new data on significant complication rates, promoters of the abortion pills are pushing new studies.

They are so cavalier about the dangers to women’s health, they insist women can determine from package instructions alone when and where it is appropriate to use the deadly drug. The goal? To make for over-the-counter (OTC) use of mifepristone,

Please follow LifeNews on Rumble for the latest pro-life videos.

In a study that seems deceptively simple and almost tangential, Lauren Ralph, Daniel Grossman, and several other abortion researchers from the University of California San Francisco and other well-known research centers across the U.S. looked not at the safety or efficacy of mifepristone, but at how well potential patients could follow, interpret, and apply package instructions when and where it is appropriate to use the deadly drug.

That study, “Accuracy of Self-Selection for Medication Abortion Using a Prototype Drug Facts Label,” appeared in the April 6, 2026, online edition of the Journal of the American Medical Association. Their largely pre-ordained conclusion was that “most [potential patients] correctly self-selected their eligibility for MA [medication abortion] after a brief, in-person interaction with a prototype OTC package and DFL [Drug Facts Label].”

The authors say this adds to previous research indicating women are largely accurate in ascertaining the gestational age (efficacy drops off and complications increase the later these pills are used in pregnancy) and in reporting their eligibility for chemical abortions. The study is intended to offer support for protocols that severely limit actual clinician involvement.

They say this is something in which American women of reproductive age are increasingly showing interest.

Study Results

For all the authors listed here (thirteen in total, many of the abortion industry’s most well know and celebrated researchers and advocates) and all the data tables and numbers, there is actually relatively little of substance in the report.

There were only 168 total subjects, representing a variety of ages, economic, and educational levels who were recruited from women seeking chemical abortion at five abortion facilities in three states (IL, MN, CO). These women were  presented with a prototype OTC mifepristone-misoprostol package insert and drug facts label. They were asked, based on that information, whether the product was “OK for [them] to use today.”

The package insert and drug facts were not available in the version of the study we saw. But there was a link that offered a two-page handout listing warnings and contraindications: “Do not use if you… are more than 10 weeks pregnant… are using an IUD… have a pregnancy outside the uterus [ectopic pregnancy]… have had surgery on your fallopian tubes… have a bleeding disorder…problems with your adrenal glands” etc. The insert continues with directions for use, expected effects, and when to seek medical help for severe pain, continued bleeding, fevers, etc.

There were no details on how a woman is to assess her gestational age beyond counting the weeks since a woman’s last menstrual period and no special advice on how to determine if she currently has an ectopic pregnancy, which the pills do not treat.

Not a whole lot else was examined in this particular study. We do not know how many of these women actually went on to receive abortion pills or how they fared if they did; whether their abortions were “successful”; or whether they suffered serious complications. Perhaps this information will be released in a follow up study.

We know generally that, according to the authors, most of these women found the package information “straightforward, clear, organized, and easy to read.”

According to the study, most of the women who did read the instructions and deemed these pills “OK to use” (93%) “expressed interest in purchasing and using an OTC MA product.”

The big finding (if there can be one with such a small sample) was that 158 of the 168 women in the study read the package and determined that they were “eligible” for chemical abortions.

But only 144 of those really met the criteria.

Fourteen women read the materials and thought they qualified but objectively didn’t. Their pregnancy was too advanced, had some condition that made them ineligible, or failed to note some medication they were taking that would compromise the abortion pill’s effectiveness.

Even among these patients who had probably already researched their options before visiting the clinic, nearly 9% made an erroneous assessment of their eligibility for abortion pills after reading the package insert.

This 9% error rate is huge, given the increased failure and complication rates that come with later gestations and the enormous risk posed by the rupture of undetected ectopic pregnancies (whose cramping and bleeding mimic chemical abortion’s process).

Nearly two-thirds of abortions in the U.S. are chemically induced. If all these pills were distributed over the counter, that would mean more than 60,000 women were making erroneous assessments per year. Because their pregnancies were likely more advanced than they estimated, they were likely to join the ranks of those facing the most serious complications.

Their data also shows that ten women read through the package materials and determined they were not eligible to receive the abortion pills. The authors say that seven of those were, in fact, eligible, but didn’t recognize it.

Though coming at it from another angle, this still shows that written instructions alone–at least as prepared by the industry’s top experts–are an inadequate tool for patients making eligibility determinations

Part of a Long Running Campaign for OTC Abortion Pills

While this shows us little about the abortion pills actual safety or efficacy, the study does reveal what the abortion industry means to accomplish going forward. Having used slanted industry studies (many by some of the same authors listed here) to gain the FDA’s original approval of mifepristone, they have continued to conduct studies since that 2000 approval, aiming to reduce or eliminate regulations imposed on the drug’s use by the agency to safeguard women’s health.

When first approved in the U.S., the FDA limited use to women whose pregnancies were no more than 49 days LMP (seven weeks past their last menstrual period) and required extensive screening, counseling and administration under a physician’s supervision in three in-person visits. Predictably, the industry found these commonsense safeguards too restrictive. They maintained that women could use abortion pills much later and did not need in-person visits with any physician.

The Obama administration heard their pleas and revised the regulations in 2016. Women whose pregnancy was ten weeks gestation (70 days LMP) could now get the pills from any certified health care provider. The number of required office visits dropped from three to one.

Abortion pill advocates were still not happy. They wanted to eliminate all required office visits and allow the pills to be prescribed by telehealth. The Biden administration readily accepted these demands. In 2021 they dropped any required visits and in 2023 allowed distribution via pharmacies.

What we see now are efforts to take this even further and let women obtain these pills over the counter, without any prescription or clinical exam or even interview. Advocates want to get rid of paperwork documenting women be informed of all risks.

But those were not insignificant risks. For example, insuring that women were screened for gestational age and eliminating the possibility of ectopic pregnancy. The abortion industry also doesn’t wish to be responsible for ensuring that patients have access to some sort of local emergency help in the event of uncontrollable bleeding.

Even the minimum safety regulations are simply too “burdensome” – not for patients, but for the abortion pill pushers.

The abortion industry is anxious to get rid of all remaining regulations. This is why many of their top researchers have come together in this study to “prove” that just having women read the packaging and labeling is safe and sufficient.

This latest study is supposed to prove that, but to the objective observer, seems to do just the opposite.

LifeNews.com Note: Randall O’Bannon, Ph.D., is the director of education and research for the National Right to Life Committee.

The post Radical Abortion Activists Want Abortion Pills Over the Counter to Kill More Babies appeared first on LifeNews.com.